Eric Dobmeier Sells 9,600 Shares of Seattle Genetics, Inc. (SGEN) Stock

Seattle Genetics, Inc. (NASDAQ:SGEN) COO Eric Dobmeier sold 9,600 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $57.80, for a total value of $554,880.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Eric Dobmeier also recently made the following trade(s):

  • On Friday, November 17th, Eric Dobmeier sold 35,000 shares of Seattle Genetics stock. The shares were sold at an average price of $58.25, for a total value of $2,038,750.00.
  • On Thursday, August 31st, Eric Dobmeier sold 25,000 shares of Seattle Genetics stock. The shares were sold at an average price of $52.24, for a total value of $1,306,000.00.
  • On Monday, August 28th, Eric Dobmeier sold 5,343 shares of Seattle Genetics stock. The shares were sold at an average price of $47.89, for a total value of $255,876.27.

Seattle Genetics, Inc. (NASDAQ SGEN) opened at $59.45 on Monday. Seattle Genetics, Inc. has a twelve month low of $45.31 and a twelve month high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The company had revenue of $135.29 million for the quarter, compared to the consensus estimate of $112.76 million. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. The company’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same period last year, the business posted ($0.23) EPS. equities analysts predict that Seattle Genetics, Inc. will post -0.93 EPS for the current fiscal year.

SGEN has been the topic of a number of analyst reports. Cann initiated coverage on Seattle Genetics in a research note on Wednesday, November 8th. They set a “hold” rating on the stock. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective on shares of Seattle Genetics in a research note on Monday, October 23rd. Goldman Sachs Group reaffirmed a “neutral” rating and set a $64.00 price objective on shares of Seattle Genetics in a research note on Friday, October 6th. TheStreet raised Seattle Genetics from a “d” rating to a “c” rating in a research note on Thursday, November 16th. Finally, Jefferies Group reissued a “buy” rating and issued a $53.00 price target on shares of Seattle Genetics in a research note on Thursday, September 14th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Seattle Genetics currently has a consensus rating of “Hold” and an average target price of $63.53.

Several institutional investors have recently added to or reduced their stakes in the company. Aperio Group LLC raised its holdings in shares of Seattle Genetics by 0.3% in the 2nd quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock worth $1,640,000 after purchasing an additional 91 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in shares of Seattle Genetics by 1.1% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 18,400 shares of the biotechnology company’s stock worth $952,000 after purchasing an additional 200 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Seattle Genetics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 4,824 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 299 shares during the period. Prudential Financial Inc. raised its holdings in shares of Seattle Genetics by 6.8% in the 2nd quarter. Prudential Financial Inc. now owns 6,291 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 400 shares during the period. Finally, Grandfield & Dodd LLC raised its holdings in shares of Seattle Genetics by 5.2% in the 2nd quarter. Grandfield & Dodd LLC now owns 10,001 shares of the biotechnology company’s stock worth $517,000 after purchasing an additional 495 shares during the period. Institutional investors own 98.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Week Herald and is owned by of Week Herald. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://weekherald.com/2017/12/04/seattle-genetics-inc-sgen-coo-eric-dobmeier-sells-9600-shares-of-stock.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply